Scantek Medical has found a Latin American distributor for a novel device that claims to detect early signs of breast disease by measuring differences in skin temperature between breast tissue. The Denville, NJ, company has licensed South American rights
Scantek Medical has found a Latin American distributor for a novel device that claims to detect early signs of breast disease by measuring differences in skin temperature between breast tissue. The Denville, NJ, company has licensed South American rights to its Breast Abnormality Indicator (BAI) to Sandell, a medical products distributor based in Montevideo, Uruguay.
BAI uses heat-sensitive pads that are placed on each breast to measure skin temperature, which may be higher in cancerous tissue due to its higher metabolic activity, according to Scantek. A temperature difference of 2F between mirror-image segments of the breasts indicates that a pathological condition may be present and that a patient should be sent on for mammography screening.
BAI is designed to be used as an adjunct to conventional mammography rather than as a replacement, according to the company. For example, it could be used to determine whether a woman under the age of 40 who might not normally receive regular mammography should be scheduled for a mammogram.
The Sandell agreement will complement a deal Scantek has with HumaScan of Cranford, NJ, which received marketing rights to BAI for the U.S. and Canada. HumaScan will sell the device as BreastAlert Differential Temperature Sensor (DTS) and plans to begin marketing the product in December. HumaScan has resolved issues that earlier this year forced the company to postpone the product's launch (SCAN 7/9/97). BAI has received 510(k) clearance from the Food and Drug Administration.
Scantek hopes to begin European sales of BAI early next year, and is lining up distribution partners for the product in that region, according to the company.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.